Stabilization of 16-oxygenated prostanoic acid derivatives
AssigneeG. D. Searle & Co.
InventorDilip R. Sanvordeker
Life of this patent
Estimating the term…
Abstract
A stable solid dosage form of the compound .+-.methyl(7-[3(.alpha.)-hydroxy-2-.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)-oxycyclopent-1.alpha.-yl]heptanoate, said solid dosage form comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrolidone per part of said compound.
Claims22
A stable solid dispersion of the compound .+-.methyl(7-[3(.alpha.)-hydroxy-2-.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)-oxycyclopent-1.alpha.-yl]heptanoate, said solid dispersion comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrolidone per part of said compound.
A stable solid dosage form of the compound .+-.methyl-(7-[3(.alpha.)-hydroxy-2.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)oxycyclopent-1.alpha.-yl]hept-4-cis-enoate, said solid dosage form comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrrolidone per part of said compound.
Dependencies are inferred from the claim text.